Silverarc Capital Management, LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Silverarc Capital Management, LLC disclosed 64 US equity positions worth $691.1m in its Q4 2025 13F filing. The largest position was ABVX at 8.2% of the reported book, followed by COGT and URGN. Against the Q3 2025 filing, it opened 9 new positions, added to 18 and reduced 23 among the top 50 holdings.
What did Silverarc Capital Management, LLC own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 8.2% | $56.9m | 422,193 | -22% | reduced | |
| 2 | COGT COGENT BIOSCIENCES INC | Healthcare | 6.4% | $44.2m | 1,245,254 | 53% | added |
| 3 | URGN UROGEN PHARMA LTD | Healthcare | 5.9% | $40.7m | 1,738,821 | 10% | added |
| 4 | 4XC1 KALVISTA PHARMACEUTICALS INC | 5.7% | $39.2m | 2,427,118 | 78% | added | |
| 5 | CELC CELCUITY INC | Healthcare | 5.4% | $37.4m | 375,132 | 323% | added |
| 6 | NUVALENT INC | 4.5% | $31.3m | 311,430 | -16% | reduced | |
| 7 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.5% | $30.9m | 750,136 | 11% | added |
| 8 | KOD KODIAK SCIENCES INC | Healthcare | 4.1% | $28.6m | 1,023,122 | 2% | added |
| 9 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.5% | $24.3m | 82,465 | 61% | added |
| 10 | IMNM IMMUNOME INC | Healthcare | 3.5% | $24.2m | 1,126,210 | – | new |
| 11 | GUTS FRACTYL HEALTH INC | 3.1% | $21.6m | 9,840,041 | -7% | reduced | |
| 12 | GLUE MONTE ROSA THERAPEUTICS INC | 2.3% | $16.1m | 1,029,066 | 48% | added | |
| 13 | VCYT VERACYTE INC | Healthcare | 2.2% | $15.1m | 357,558 | 52% | added |
| 14 | CGON CG ONCOLOGY INC | Healthcare | 2.2% | $15.0m | 361,158 | -43% | reduced |
| 15 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.1% | $14.6m | 135,950 | -63% | reduced |
| 16 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.0% | $13.5m | 642,899 | 39% | added |
| 17 | BIIB BIOGEN INC | Healthcare | 1.9% | $13.3m | 75,412 | -6% | reduced |
| 18 | INSM INSMED INC | Healthcare | 1.8% | $12.4m | 71,256 | -66% | reduced |
| 19 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.7% | $11.5m | 458,203 | 224% | added | |
| 20 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.6% | $10.8m | 348,569 | 34% | added |
| 21 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.5% | $10.5m | 49,228 | -8% | reduced |
| 22 | PFE PFIZER INC | Healthcare | 1.5% | $10.4m | 419,134 | – | new |
| 23 | BENITEC BIOPHARMA INC | 1.4% | $9.9m | 731,717 | 165% | added | |
| 24 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.4% | $9.5m | 524,436 | -27% | reduced |
| 25 | GH GUARDANT HEALTH INC | Healthcare | 1.4% | $9.4m | 91,914 | – | new |
| 26 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.3% | $9.1m | 1,116,604 | -43% | reduced |
| 27 | PCVX VAXCYTE INC | Healthcare | 1.0% | $6.9m | 148,787 | -53% | reduced |
| 28 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.0% | $6.8m | 541,240 | -8% | reduced |
| 29 | GOSS GOSSAMER BIO INC | Healthcare | 1.0% | $6.6m | 2,135,722 | -55% | reduced |
| 30 | SYRE SPYRE THERAPEUTICS INC | 0.9% | $6.2m | 187,737 | – | new | |
| 31 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.9% | $6.1m | 617,608 | -21% | reduced |
| 32 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 0.9% | $6.1m | 506,242 | -28% | reduced |
| 33 | CERS CERUS CORP | Healthcare | 0.8% | $5.8m | 2,814,383 | 4% | added |
| 34 | CMPX COMPASS THERAPEUTICS INC | 0.8% | $5.6m | 1,051,343 | -63% | reduced | |
| 35 | SLNOEUR SOLENO THERAPEUTICS INC | 0.8% | $5.4m | 117,485 | – | new | |
| 36 | CGEN COMPUGEN LTD | Healthcare | 0.8% | $5.3m | 3,479,805 | 5% | added |
| 37 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.8% | $5.2m | 191,074 | -45% | reduced |
| 38 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.7% | $5.2m | 206,280 | -78% | reduced |
| 39 | ERAS ERASCA INC | Healthcare | 0.7% | $4.9m | 1,317,584 | -4% | reduced |
| 40 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.6% | $4.5m | 394,650 | – | new |
| 41 | AARD AARDVARK THERAPEUTICS INC | 0.6% | $4.0m | 303,939 | -1% | reduced | |
| 42 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.6% | $3.8m | 1,994,224 | 5% | added |
| 43 | SRZN SURROZEN INC | 0.5% | $3.6m | 157,323 | – | new | |
| 44 | CTNM CONTINEUM THERAPEUTICS INC | 0.5% | $3.5m | 307,540 | 85% | added | |
| 45 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.5% | $3.4m | 94,983 | 19% | added |
| 46 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.5% | $3.4m | 398,167 | – | new |
| 47 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 0.5% | $3.3m | 627,738 | -37% | reduced |
| 48 | TELA TELA BIO INC | 0.5% | $3.1m | 2,647,512 | -5% | reduced | |
| 49 | QURE UNIQURE NV | 0.4% | $3.0m | 126,047 | -72% | reduced | |
| 50 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.4% | $3.0m | 36,124 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.